Archive for the ‘bioquark’ tag: Page 19
Jan 15, 2018
Bioquark Inc. — Dr. Gayle Carson / Living Regret Free — Ira Pastor
Posted by Ira S. Pastor in categories: aging, biotech/medical, cryonics, DNA, futurism, genetics, health, life extension, neuroscience, science
Jan 11, 2018
Playboy — DNA To Find The One — Bioquark Commentary
Posted by Ira S. Pastor in categories: biological, biotech/medical, business, DNA, finance, genetics, health, philosophy, science, sex
Jul 5, 2017
Revita Life Sciences Continues to Advance Multi-Modality Protocol in Attempt to Revive Brain Dead Subjects
Posted by Ira S. Pastor in categories: bioengineering, biotech/medical, cryonics, futurism, genetics, health, life extension, neuroscience, posthumanism
Rudrapur, Uttrakhand, India — July 02, 2017
Revita Life Sciences, (http://revitalife.co.in) a biotechnology company focused on translational regenerative therapeutic applications, has announced that it is continuing to advance their novel, multi-modality clinical intervention in the state of brain death in humans.
“We have proactively continued to advance our multi-modality protocol, as an extended treatment before extubation, in an attempt to reverse the state of brain death” said Mr.Pranjal Agrawal, CEO Revita Life Sciences. “This treatment approach has yielded some very encouraging initial outcome signs, ranging from minor observations on blood pressure changes with response to painful stimuli, to eye opening and finger movements, with corresponding transient to permanent reversal changes in EEG patterns.”
Feb 22, 2017
Bioquark Inc. and SC21 Biotech to Collaborate on Novel Cellular Therapies for Long Term HIV Control
Posted by Ira S. Pastor in categories: bioengineering, biotech/medical, business, disruptive technology, DNA, genetics, health, science, sex
Orginal press: http://www.prweb.com/releases/2017/02/prweb14062199.htm
Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel biologics for complex regeneration and disease reversion, and SC21 Biotech, (http://www.sc21bio.tech), a biotechnology company focused on translational therapeutic applications of autologous stem cell therapy, have announced a collaboration to focus on novel cellular reprogramming and production approaches for CCR5 Delta32 homozygous cord blood stem cells, for long-term control of HIV via transplantation.
“We are very excited about this collaboration with SC21 Biotech,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular reprogramming tools and SC21 Biotech’s translational cell therapy experience, will make for a transformational opportunity in this area of HIV disease control.”
Jan 5, 2017
Bioquark Inc. Announces Approval of Bioquantine Food Ingredients in Eurasian Customs Union
Posted by Ira S. Pastor in categories: aging, biotech/medical, business, disruptive technology, food, genetics, health, life extension, science, transhumanism
Philadelphia, PA, USA / Moscow, Russia — Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, announced the commercial approval of naturally derived Bioquantine food ingredients in the Eurasian Customs Union (formerly known as the Customs Union of Belarus, Kazakhstan, and Russia). Moscow based, Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, collaborated with Bioquark Inc. on the regulatory approvals.
“We are very excited about this successful regulatory approval,” said Ira S. Pastor, CEO, Bioquark Inc. “The commercialization of Bioquantine food ingredients, including functional foods, drinks, and dietary supplements, represents another important step in our continued evolution as a company focused on a broad range of products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
Nov 1, 2016
Who wants to live forever?
Posted by Ira S. Pastor in categories: aging, bioengineering, cryonics, disruptive technology, DNA, futurism, genetics, health, life extension, posthumanism
Bioquark Inc. (www.bioquark.com) Interview in MoneyWeek
Read whole story: http://moneyweek.com/who-wants-to-live-forever/
Oct 25, 2016
10 companies that want to make chemotherapy easier for patients — Bioquark Inc.
Posted by Ira S. Pastor in categories: aging, bioengineering, biological, biotech/medical, disruptive technology, DNA, genetics, health, life extension, science
Bioquark Inc. (www.bioquark.com) mention on CNBC — the best way to make chemo easier is to eliminate the need for it forever!
Continue reading “10 companies that want to make chemotherapy easier for patients — Bioquark Inc.” »
Aug 2, 2016
Bioquark Inc. and RegenerAge SAPI de CV to Collaborate on Clinical Regenerative Healthcare
Posted by Ira S. Pastor in categories: aging, bioengineering, biotech/medical, DNA, health, life extension, neuroscience, posthumanism, science, transhumanism
Philadelphia, PA, USA / Mexico City, Mexico — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bioproducts for complex regeneration, disease reversion, and aging, and RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on translational therapeutic applications of a range of regenerative and rejuvenation healthcare interventions, have announced a collaboration to focus on novel combinatorial approaches in human disease and wellness. SGR-Especializada (http://www.sgr-especializada.com/), regulatory experts in the Latin American healthcare market, assisted in the relationship.
“We are very excited about this collaboration with RegenerAge SAPI de CV,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular and biologic to applications of regenerative and rejuvenative medicine will make for novel and transformational opportunities in a range of degenerative disorders.”
As we close in on $7 trillion in total annual health care expenditures around the globe ($1 trillion spent on pharmaceutical products; $200 billion on new R&D), we are simultaneously witnessing a paradoxical rise in the prevalence of all chronic degenerative diseases responsible for human suffering and death.
